A novel treatment target for Parkinson's disease

Journal of the Neurological Sciences

Volumn 347, Issue 1-2, 2014, Pages 34-38

  Wakade, Chandramohan ^a   Chong, Raymond ^a  

^a AUGUSTA UNIVERSITY   (United States)

Author keywords

GPR109A; HCAR2; HM74a; Inflammation; Niacin; Niacinamide

Indexed keywords

BUTYRIC ACID DERIVATIVE; DOPAMINE; GPR109A RECEPTOR; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINIC ACID; RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; HCAR2 PROTEIN, HUMAN; NEUROPROTECTIVE AGENT; NICOTINIC AGENT; NICOTINIC RECEPTOR;

CORPUS STRIATUM; DEPLETION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINE METABOLISM; DRUG TARGETING; HUMAN; INFLAMMATION; INTESTINE; KETOGENIC DIET; MITOCHONDRION; MOLECULAR MECHANICS; PARKINSON DISEASE; PROTEIN FUNCTION; RETINA; REVIEW; SECOND MESSENGER; SKIN; UPREGULATION; AGED; AGONISTS; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED;

AGED; DOPAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAD; NEUROPROTECTIVE AGENTS; NIACIN; NICOTINIC AGONISTS; PARKINSON DISEASE; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; UP-REGULATION;

EID: 84920053894     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.10.024     Document Type: Review

References (47)

1. P.A. Fall, M. Fredrikson, O. Axelson, and A.K. Granerus Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden Mov Disord 14 1 1999 28 37
2. W. Hellenbrand, H. Boeing, B.P. Robra, A. Seidler, P. Vieregge, and P. Nischan Diet and Parkinson's disease. II: a possible role for the past intake of specific nutrients.
3. J.M. Alisky Niacin improved rigidity and bradykinesia in a Parkinson's disease patient but also caused unacceptable nightmares and skin rash - a case report Nutr Neurosci 8 5-6 2005 327 329
4. M.R. Hoane, A.A. Tan, J.L. Pierce, G.D. Anderson, and D.C. Smith Nicotinamide treatment reduces behavioral impairments and provides cortical protection after fluid percussion injury in the rat J Neurotrauma 23 10 2006 1535 1548
5. D.W. Anderson, K.A. Bradbury, and J.S. Schneider Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism Eur J Neurosci 28 3 2008 610 617
6. M. Karobath, J.L. Diaz, and M.O. Huttunen The effect of L-dopa on the concentrations of tryptophan, tyrosine and serotonin in rat brain Eur J Pharmacol 14 4 1971 393 396
7. T. Ogawa, W.R. Matson, M.F. Beal, R.H. Myers, E.D. Bird, and P. Milbury Kynurenine pathway abnormalities in Parkinson's disease Neurology 42 9 1992 1702 1706
8. C.E. Stafstrom, and J.M. Rho The ketogenic diet as a treatment paradigm for diverse neurological disorders Front Pharmacol 3 2012 59
9. H.M. Gao, B. Liu, W. Zhang, and J.S. Hong Novel anti-inflammatory therapy for Parkinson's disease Trends Pharmacol Sci 24 8 2003 395 401
10. S. Hunot, and E.C. Hirsch Neuroinflammatory processes in Parkinson's disease Ann Neurol 53 Suppl. 3 2003 S49 S58 (discussion S-60)
11. B. Widner, F. Leblhuber, and D. Fuchs Increased neopterin production and tryptophan degradation in advanced Parkinson's disease J Neural Transm 109 2 2002 181 189
12. S. Offermanns The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target Trends Pharmacol Sci 27 7 2006 384 390
13. T. Gharbaoui, P.J. Skinner, Y.J. Shin, C. Averbuj, J.K. Jung, and B.R. Johnson Agonist lead identification for the high affinity niacin receptor GPR109a Bioorg Med Chem Lett 17 17 2007 4914 4919
14. J.E. Digby, F. Martinez, A. Jefferson, N. Ruparelia, J. Chai, and M. Wamil Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms Arterioscler Thromb Vasc Biol 32 3 2012 669 676
15. D. Maciejewski-Lenoir, J.G. Richman, Y. Hakak, I. Gaidarov, D.P. Behan, and D.T. Connolly Langerhans cells release prostaglandin D2 in response to nicotinic acid J Investig Dermatol 126 12 2006 2637 2646
16. J.P. Segain, D. Raingeard de la Bletiere, A. Bourreille, V. Leray, N. Gervois, and C. Rosales Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease Gut 47 3 2000 397 403
17. Z. Benyo, A. Gille, J. Kero, M. Csiky, M.C. Suchankova, and R.M. Nusing GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing J Clin Invest 115 12 2005 3634 3640
18. M. Thangaraju, G.A. Cresci, K. Liu, S. Ananth, J.P. Gnanaprakasam, and D.D. Browning GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon Cancer Res 69 7 2009 2826 2832
19. M.S. Inan, R.J. Rasoulpour, L. Yin, A.K. Hubbard, D.W. Rosenberg, and C. Giardina The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line Gastroenterology 118 4 2000 724 734
20. D. Gambhir, S. Ananth, R. Veeranan-Karmegam, S. Elangovan, S. Hester, and E. Jennings GPR109A as an anti-inflammatory receptor in retinal pigment epithelial cells and its relevance to diabetic retinopathy Invest Ophthalmol Vis Sci 53 4 2012 2208 2217
21. P.C. Chang, L.Y. Chien, J.F. Yeo, Y.P. Wang, M.C. Chung, and L.Y. Chong Progression of periodontal destruction and the roles of advanced glycation end-products in experimental diabetes J Periodontol 84 3 2012 379 388 10.1902/jop.2012.120076
22. V.S. Kamanna, S.H. Ganji, and M.L. Kashyap The mechanism and mitigation of niacin-induced flushing Int J Clin Pract 63 9 2009 1369 1377
23. E.P. Plaisance, M. Lukasova, S. Offermanns, Y. Zhang, G. Cao, and R.L. Judd Niacin stimulates adiponectin secretion through the GPR109A receptor Am J Physiol Endocrinol Metab 296 3 2009 E549 E558
24. W. Song, T. Huo, F. Guo, H. Wang, H. Wei, and Q. Yang Globular adiponectin elicits neuroprotection by inhibiting NADPH oxidase-mediated oxidative damage in ischemic stroke Neuroscience 248C 2013 136 144
25. H. Shafique, A. Blagrove, A. Chung, and R. Logendrarajah Causes of Parkinson's disease: literature review J Parkinsonism Restless Leg Syndr 1 1 2011 5 7
26. H. Jia, X. Li, H. Gao, Z. Feng, L. Zhao, and X. Jia High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease J Neurosci Res 86 9 2008 2083 2090
27. C. Vives-Bauza, M. Tocilescu, R.L. Devries, D.M. Alessi, V. Jackson-Lewis, and S. Przedborski Control of mitochondrial integrity in Parkinson's disease Prog Brain Res 183 2010 99 113
28. P. Belenky, F.G. Racette, K.L. Bogan, J.M. McClure, J.S. Smith, and C. Brenner Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD + Cell 129 3 2007 473 484
29. P.W. Piper, N.L. Harris, and M. MacLean Preadaptation to efficient respiratory maintenance is essential both for maximal longevity and the retention of replicative potential in chronologically ageing yeast Mech Ageing Dev 127 9 2006 733 740
30. Y. Sasaki, T. Araki, and J. Milbrandt Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy J Neurosci 26 33 2006 8484 8491
31. D.M. Arduino, A.R. Esteves, C.R. Oliveira, and S.M. Cardoso Mitochondrial metabolism modulation: a new therapeutic approach for Parkinson's disease CNS Neurol Disord Drug Targets 9 1 2010 105 119
32. K. Vrecko, J.G. Birkmayer, and J. Krainz Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotinamide adeninedinucleotide (NADH) J Neural Transm 5 2 1993 147 156
33. K. Vrecko, D. Storga, J.G. Birkmayer, R. Moller, E. Tafeit, and R. Horejsi NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaeochromocytoma cells Biochim Biophys Acta 1361 1 1997 59 65
34. W. Birkmayer, and G.J. Birkmayer Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's disease Ann Clin Lab Sci 19 1 1989 38 43
35. J.G. Birkmayer, C. Vrecko, D. Volc, and W. Birkmayer Nicotinamide adenine dinucleotide (NADH) - a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application Acta Neurol Scand Suppl 146 1993 32 35
36. R.B. Postuma, J.F. Gagnon, and J. Montplaisir Clinical prediction of Parkinson's disease: planning for the age of neuroprotection J Neurol Neurosurg Psychiatry 81 9 2010 1008 1013
37. M. Barichella, E. Cereda, and G. Pezzoli Major nutritional issues in the management of Parkinson's disease Mov Disord 24 13 2009 1881 1892
38. A. Navarro, and A. Boveris Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease Front Aging Neurosci 2 2010
39. The Unified Parkinson's Disease Rating Scale (UPDRS) Status and recommendations Mov Disord 18 7 2003 738 750
40. A. Salarian, C. Zampieri, F.B. Horak, P. Carlson-Kuhta, J.G. Nutt, and K. Aminian Analyzing 180 degrees turns using an inertial system reveals early signs of progression of Parkinson's disease IEEE Eng Med Biol Soc Conf 2009 2009 224 227
41. A. Salarian, F.B. Horak, C. Zampieri, P. Carlson-Kuhta, J.G. Nutt, and K. Aminian iTUG, a sensitive and reliable measure of mobility IEEE Trans Neural Syst Rehabil Eng 18 3 2010 303 310
42. N. Chastan, B. Debono, D. Maltete, and J. Weber Discordance between measured postural instability and absence of clinical symptoms in Parkinson's disease patients in the early stages of the disease Mov Disord 23 3 2008 366 372
43. R.K. Chong, F.B. Horak, J. Frank, and J. Kaye Sensory organization for balance: specific deficits in Alzheimer's but not in Parkinson's disease J Gerontol A Biol Sci Med Sci 54 3 1999 M122 M128
44. R.K. Chong, C.L. Jones, and F.B. Horak Postural set for balance control is normal in Alzheimer's but not in Parkinson's disease J Gerontol A Biol Sci Med Sci 54 3 1999 M129 M135
45. R.K. Chong, F.B. Horak, and M.H. Woollacott Parkinson's disease impairs the ability to change set quickly J Neurol Sci 175 1 2000 57 70
46. R.K. Chong, K.Y. Lee, and J.H. Lee Visuomotor prism adaptation deficits in Parkinson's disease Society for Neuroscience annual conference, Washington, DC 272 2008 (10)
47. P.C. Poluha, H.L. Teulings, and R.H. Brookshire Handwriting and speech changes across the levodopa cycle in Parkinson's disease Acta Psychol (Amst) 100 1-2 1998 71 84